Whilst Shield Therapeutics plc (the “Company”) has taken reasonable care to ensure that the information on this website (other than information accessed by hypertext link) is accurate at the time of last revision of the website, the Company accepts no liability for the accuracy or completeness or use of, nor any liability to update, the information contained on this website. It should not be construed as the giving of advice or the making of a recommendation and should not be relied on as the basis for any decision or action. In particular, actual results and developments may be materially different from any opinion or expectation expressed on this website.
Certain information on this website is of a historical nature and may now be out of date. All historical information should be understood as speaking from the date of its first publication.
Nothing on this website constitutes an invitation or offer to invest or deal in any securities of the Company or any of its subsidiaries. This website may contain certain hypertext links to other websites. The Company has not reviewed, is not responsible for, and accepts no liability in respect of, any information or opinion contained on any such other website.
The website and the information to which this gatepost gives access is not intended for, and may not be accessed by, or distributed or disseminated to, persons resident or physically present in the United States of America (including its territories, the “United States”), Australia, Canada, Japan or South Africa. The information does not constitute an offer to sell or the solicitation of an offer to purchase or subscribe for, any securities of the Company in the United States, Australia, Canada, Japan or South Africa or in any other jurisdiction in which such offer, solicitation, invitation, sale, purchase or subscription is unauthorised or to any person whom it is unlawful to make such offer.
The Company’s securities cannot be offered or sold in the United States without registration under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or pursuant to an exemption from such registration. The securities of the Company referred to on this website have not been and will not be registered under the U.S. Securities Act.
Potential users of this information are requested to inform themselves about and to observe any such restrictions. All persons residing outside of the United States, Australia, Canada, Japan and South Africa who wish to access the documents contained on this website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this website, or require registration or approval for any acquisition of securities by them. The Company assumes no responsibility if there is a violation of applicable law and regulations by any person.
The Company has not authorised any public offering in any Member State of the European Economic Area other than the United Kingdom. With respect to any Member State of the European Economic Area, other than the United Kingdom, that has implemented Directive 2003/71/EC and Directive 2010/73/EU (together with any applicable implementing measures in any Member State, the “Prospectus Directive”), this website and the information contained herein, or to which it gives access, is only addressed to, and is only directed at, qualified investors in that Member State within the meaning of the Prospectus Directive.
In addition, in the United Kingdom, this website and the information contained herein, or to which it gives access, is addressed to, and directed only at: (a) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”), and (b) high net worth entities, and other persons to whom they may otherwise lawfully be communicated, falling within Article 49(2) of the Order (all such persons together being referred to as “Relevant Persons”). In the United Kingdom, any investment or investment activity to which this website and the information contained herein, or to which it gives access, relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. Any person in the United Kingdom who is not a Relevant Person should not act or rely on this website and the information contained herein, or to which it gives access.
If you are not permitted to view materials on this website or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.
By proceeding to view the materials to which this gatepost gives access, you warrant that you are not a resident of or physically present in the United States, Australia, Canada, Japan or South Africa or any other restricted jurisdiction and are not a U.S. person (as defined in Regulation S under the U.S. Securities Act), and that you are either: (a) a resident of, and domiciled in the United Kingdom, (b) a resident of, and domiciled in, a Member State of the European Economic Area other than the United Kingdom and a qualified investor within the meaning of the Prospectus Directive, (c) a resident of, and domiciled in, the United Kingdom, a qualified investor within the meaning of the Prospectus Directive and a Relevant Person, or (d) otherwise authorised to access this information pursuant to applicable laws or regulations.